Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364012 | PMC |
| http://dx.doi.org/10.1186/s12883-021-02326-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
J Neurooncol
May 2022
Department of Neurosurgery, Computational Neuroscience Outcomes Center, Brigham and Women's Hospital, Boston, MA, USA.
Purpose: Gliosarcoma is an uncommon glioblastoma subtype, for which MGMT promoter methylation's relationship with response to temozolomide chemotherapy is unclear. We therefore examined this question using a national cohort.
Methods: The National Cancer Database was queried for patients histopathologically diagnosed with gliosarcoma between 2010 and 2019.
CNS Histoplasmosis as a Gliosarcoma mimicker: The diagnostic dilemma of solitary brain lesions.
IDCases
December 2021
University of Missouri, Division of Infectious Diseases, Columbia, MO, USA.
Histoplasmosis is usually a benign, self-limited disease with lungs predilection. However, it might manifest as a disseminated disease in immunocompromised individuals. The involvement of the central nervous system (CNS) accounts for about 5-10% of cases with disseminated disease.
View Article and Find Full Text PDFCorrigendum: Machine Learning-Based Analysis of Magnetic Resonance Radiomics for the Classification of Gliosarcoma and Glioblastoma.
Front Oncol
October 2021
Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
[This corrects the article DOI: 10.3389/fonc.2021.
View Article and Find Full Text PDFCorrection to: Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.
BMC Neurol
August 2021
Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Synthesis, Radiolabeling, and Biological Evaluation of the -Stereoisomers of 1-Amino-3-(fluoro-F)-4-fluorocyclopentane-1-carboxylic Acid as PET Imaging Agents.
ACS Pharmacol Transl Sci
June 2021
Department of Radiology and Imaging Sciences, Department of Neurosurgery, School of Medicine, Emory University, 1364 Clifton Road NE, Atlanta, Georgia 30322, United States.
The enantiomeric non-natural cyclic amino acids (3,4)-1-amino-3-fluoro-4-(fluoro-F)cyclopentane-1-carboxylic acid and (3,4)-1-amino-3-fluoro-4-(fluoro-F)cyclopentane-1-carboxylic acid ( ) have been prepared as a racemic mixture in 1.3% decay corrected radiochemical yield and in greater than 99% radiochemical purity. is transported primarily via system L with some transport occurring via system ASC, as assessed in rat 9L gliosarcoma, human U87 ΔEGFR glioblastoma, and human DU145 androgen-independent prostate carcinoma tumor cells.
View Article and Find Full Text PDF